Travere Therapeutics, Inc. $TVTX Shares Sold by AQR Capital Management LLC

AQR Capital Management LLC lowered its stake in Travere Therapeutics, Inc. (NASDAQ:TVTX) by 5.8% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 399,310 shares of the company’s stock after selling 24,714 shares during the period. AQR Capital Management LLC owned 0.45% of Travere Therapeutics worth $7,156,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of the company. GF Fund Management CO. LTD. acquired a new stake in Travere Therapeutics during the fourth quarter valued at approximately $31,000. Caitong International Asset Management Co. Ltd acquired a new position in Travere Therapeutics in the first quarter worth $62,000. KBC Group NV bought a new stake in Travere Therapeutics during the first quarter valued at $75,000. Wealth Enhancement Advisory Services LLC acquired a new stake in shares of Travere Therapeutics during the first quarter worth $182,000. Finally, Twinbeech Capital LP acquired a new position in shares of Travere Therapeutics in the 4th quarter valued at about $177,000.

Travere Therapeutics Trading Down 8.5%

NASDAQ:TVTX opened at $25.00 on Friday. The stock has a market cap of $2.23 billion, a price-to-earnings ratio of -12.25 and a beta of 0.79. The business has a fifty day moving average of $17.55 and a 200-day moving average of $17.38. Travere Therapeutics, Inc. has a 1 year low of $11.89 and a 1 year high of $28.69. The company has a debt-to-equity ratio of 9.50, a quick ratio of 1.98 and a current ratio of 2.00.

Travere Therapeutics (NASDAQ:TVTX) last announced its earnings results on Wednesday, August 6th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.14. The firm had revenue of $94.84 million during the quarter, compared to analyst estimates of $100.18 million. Travere Therapeutics had a negative net margin of 50.64% and a negative return on equity of 717.68%. Travere Therapeutics’s revenue was up 111.5% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.65) EPS. Equities analysts predict that Travere Therapeutics, Inc. will post -1.4 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the stock. Jefferies Financial Group set a $35.00 price objective on shares of Travere Therapeutics in a research note on Wednesday. Scotiabank reaffirmed an “outperform” rating on shares of Travere Therapeutics in a report on Thursday, August 7th. Wall Street Zen raised Travere Therapeutics from a “hold” rating to a “buy” rating in a report on Monday, September 1st. HC Wainwright restated a “buy” rating and set a $47.00 price objective on shares of Travere Therapeutics in a research report on Wednesday. Finally, Wedbush increased their target price on Travere Therapeutics from $30.00 to $32.00 and gave the stock an “outperform” rating in a research report on Thursday, August 7th. Thirteen analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $34.07.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.